111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血清 GSDMD 在心力衰竭患者中的诊断及预后价值：一项回顾性研究
Authors Wei C, Ding N , Liu X , Yu F, Huo L , Pei Y, Li X, Yang C
Received 22 August 2025
Accepted for publication 27 November 2025
Published 10 December 2025 Volume 2025:18 Pages 7447—7457
DOI https://doi.org/10.2147/IJGM.S562238
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Redoy Ranjan
Changmei Wei, Nan Ding, Xuexin Liu, Fang Yu, Lijing Huo, Yunli Pei, Xinxin Li, Chaoju Yang
Department of Medical Laboratory, Hebei General Hospital, Shijiazhuang, Hebei Province, People’s Republic of China
Correspondence: Lijing Huo, Department of Medical Laboratory, Hebei General Hospital, 348 Heping West Road, Xinhua District, Shijiazhuang, Hebei Province, People’s Republic of China, Email huolijing1979@126.com
Objective: This study analyzes the value of serum Gasdermin D (GSDMD) as a novel biomarker for the early diagnosis and disease progression of heart failure.
Methods: We conducted a retrospective analysis of clinical data and laboratory results to compare the GSDMD levels among the heart failure group, other cardiac disease group, and healthy control group. We investigates the correlation between GD and other indicators, as well as the independent risk factors for heart failure. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic value of serum GSDMD, N-terminal pro-B-type natriuretic peptide (NT-ProBNP), ejection fraction (EF) in patients.
Results: There were statistically significant differences in serum GSDMD, EF and other laboratory tests among the three groups (P< 0.05). Among heart failure patients with different cardiac function classifications, the serum levels of NT-ProBNP, GSDMD increased with the increase in cardiac function classification. Serum GSDMD was correlated with all indicators (P< 0.05) in subjects. Serum GSDMD and NT-ProBNP were independent risk factors while EF was an independent protective factor for heart failure. The AUCs of serum GSDMD, NT ProBNP, and EF for diagnosing heart failure were 0.819, 0.970, and 0.831, respectively, while the AUC of their combined diagnosis of heart failure was 0.986.
Conclusion: This study suggests that Serum GSDMD, as a novel sensitive biomarker, has the potential for early diagnosis and disease progression assessment of heart failure.
Keywords: heart failure, serum GSDMD, diagnostic value
Department of Medical Laboratory, Hebei General Hospital, Shijiazhuang, Hebei Province, People’s Republic of China
Correspondence: Lijing Huo, Department of Medical Laboratory, Hebei General Hospital, 348 Heping West Road, Xinhua District, Shijiazhuang, Hebei Province, People’s Republic of China, Email huolijing1979@126.com
Objective: This study analyzes the value of serum Gasdermin D (GSDMD) as a novel biomarker for the early diagnosis and disease progression of heart failure.
Methods: We conducted a retrospective analysis of clinical data and laboratory results to compare the GSDMD levels among the heart failure group, other cardiac disease group, and healthy control group. We investigates the correlation between GD and other indicators, as well as the independent risk factors for heart failure. Receiver operating characteristic (ROC) curve analysis was conducted to compare the diagnostic value of serum GSDMD, N-terminal pro-B-type natriuretic peptide (NT-ProBNP), ejection fraction (EF) in patients.
Results: There were statistically significant differences in serum GSDMD, EF and other laboratory tests among the three groups (P< 0.05). Among heart failure patients with different cardiac function classifications, the serum levels of NT-ProBNP, GSDMD increased with the increase in cardiac function classification. Serum GSDMD was correlated with all indicators (P< 0.05) in subjects. Serum GSDMD and NT-ProBNP were independent risk factors while EF was an independent protective factor for heart failure. The AUCs of serum GSDMD, NT ProBNP, and EF for diagnosing heart failure were 0.819, 0.970, and 0.831, respectively, while the AUC of their combined diagnosis of heart failure was 0.986.
Conclusion: This study suggests that Serum GSDMD, as a novel sensitive biomarker, has the potential for early diagnosis and disease progression assessment of heart failure.
Keywords: heart failure, serum GSDMD, diagnostic value